Relay Therapeutics, Inc. (RLAY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on July 16, 2024, reporting an event that occurred on July 11, 2024. The filing addresses the termination of a material definitive agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures. It references historical consideration received under the terminated agreement:
- Total Consideration Received: $121.8 million
- Upfront Payment: $75.0 million
- Milestone Payments: $45.0 million
- Other: Reimbursement of certain research and development costs
Material Changes
On July 11, 2024, Genentech elected to terminate the Collaboration and License Agreement dated December 11, 2020, without cause. Key implications include:
- Effective Date: Termination becomes effective 180 days after the notice date (the "Termination Date").
- Future Payments: The Company will not receive any further milestones or payments due after the Termination Date.
- Operational Impact: Both parties will cease development and commercialization obligations for the asset RLY-1971 (migoprotafib/GDC-1971) after the Termination Date.
- Licensing: Licenses granted to Genentech will cease to be effective as of the Termination Date.
Outlook, Risks, and Management Commentary
The filing indicates a significant reduction in future revenue potential from this specific partnership. The Company will no longer have development or commercialization obligations for migoprotafib under this agreement. No specific financial guidance or updated outlook was provided in this document. The primary risk identified is the loss of future milestone payments and the cessation of the collaborative development of the Src homology region 2 domain-containing phosphatase-2 inhibitor.
Investor Verification Checklist
- Verify the exact date the 180-day termination period concludes to determine when licenses and obligations officially cease.
- Review the Company's most recent Form 10-K to understand the full scope of the terminated agreement and any remaining contractual obligations.
- Assess the impact of losing the Genentech partnership on the Company's overall cash runway and future funding requirements.
- Confirm whether the Company retains rights to migoprotafib for independent development or if rights revert to Genentech upon termination.